

## Key Updates in Bispecific Antibodies in NHL Management—Unmet Needs and Opportunities for Improved Management in Later-Line Management

### Toolkit

#### Overview of B-Cell Non-Hodgkin Lymphomas

Reference	URL
Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: Moving toward a molecularly targeted approach. <i>Blood</i> . 2005;106:1164-1174.	<a href="https://ashpublications.org/blood/article/106/4/1164/21561/Advances-in-the-biology-and-therapy-of-diffuse">https://ashpublications.org/blood/article/106/4/1164/21561/Advances-in-the-biology-and-therapy-of-diffuse</a>
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. <i>Nature</i> . 2000;403:503-511.	<a href="https://www.nature.com/articles/35000501">https://www.nature.com/articles/35000501</a>
American Cancer Society (ACS). Key statistics for non-Hodgkin lymphoma. Last revised January 17, 2024.	<a href="https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/key-statistics.html">https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/key-statistics.html</a>
Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. <i>J Clin Oncol</i> . 1998;16:2780-2795.	<a href="https://ascopubs.org/doi/10.1200/JCO.1998.16.8.2780">https://ascopubs.org/doi/10.1200/JCO.1998.16.8.2780</a>
Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nat Med</i> . 2018;24:1290-1291.	<a href="https://www.nature.com/articles/s41591-018-0016-8">https://www.nature.com/articles/s41591-018-0016-8</a>
Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. <i>N Engl J Med</i> . 2002;346:235-242.	<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa011795">https://www.nejm.org/doi/full/10.1056/NEJMoa011795</a>
Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte. <i>Blood</i> . 2010;116:2040-2045.	<a href="https://ashpublications.org/blood/article/116/12/2040/27477/Long-term-outcome-of-patients-in-the-LNH-98-5">https://ashpublications.org/blood/article/116/12/2040/27477/Long-term-outcome-of-patients-in-the-LNH-98-5</a>
de Leval L, Alizadeh AA, Bergsagel PL, et al. Genomic profiling for clinical decision making in lymphoid neoplasms. <i>Blood</i> . 2022;24:140:2193-2227.	<a href="https://ashpublications.org/blood/article/140/21/2193/486384/Genomic-profiling-for-clinical-decision-making-in">https://ashpublications.org/blood/article/140/21/2193/486384/Genomic-profiling-for-clinical-decision-making-in</a>
Dunleavy K. Aggressive B cell lymphoma: Optimal therapy for MYC-positive, double-hit, and triple-hit DLBCL. <i>Curr Treat Options Oncol</i> . 2015;16:58.	<a href="https://link.springer.com/article/10.1007/s11864-015-0374-0">https://link.springer.com/article/10.1007/s11864-015-0374-0</a>
Eyre TA, Savage KJ, Cheah CY, et al. CNS prophylaxis for diffuse large B-cell lymphoma. <i>Lancet Oncol</i> . 2022;23:e416-e426.	<a href="https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00371-0/abstract">https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00371-0/abstract</a>
Leukemia and Lymphoma Society. NHL Subtypes.	<a href="https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes">https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes</a>
Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. <i>Am J Transplant</i> . 2006;6:859-866.	<a href="https://www.amjtransplant.org/article/S1600-6135(22)02663-6/fulltext">https://www.amjtransplant.org/article/S1600-6135(22)02663-6/fulltext</a>

Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. <i>N Engl J Med</i> . 2018;378:1396-1407.	<a href="https://www.nejm.org/doi/10.1056/NEJMoa1801445">https://www.nejm.org/doi/10.1056/NEJMoa1801445</a>
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood</i> . 2016;127:2375-2390.	<a href="https://ashpublications.org/blood/article/127/20/2375/35286/The-2016-revision-of-the-World-Health-Organization">https://ashpublications.org/blood/article/127/20/2375/35286/The-2016-revision-of-the-World-Health-Organization</a>
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. <i>N Engl J Med</i> . 1993;329:987-994.	<a href="https://www.nejm.org/doi/full/10.1056/nejm199309303291402">https://www.nejm.org/doi/full/10.1056/nejm199309303291402</a>
Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. <i>J Clin Oncol</i> . 2010;28:2373-2380.	<a href="https://ascopubs.org/doi/10.1200/JCO.2009.26.2493">https://ascopubs.org/doi/10.1200/JCO.2009.26.2493</a>

### Developments in Therapy for B-NHL

Reference	URL
Caimi PF, Ai WZ, Alderuccio JP, et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase 2 LOTIS-2 study. <i>Haematologica</i> . Published online August 31, 2023.	<a href="https://haematologica.org/article/view/haematol.2023.283459">https://haematologica.org/article/view/haematol.2023.283459</a>
Chiu C, Hiemstra IH, Johnson P, et al. Evaluation of pharmacodynamic biomarkers of epcoritamab (GEN3013; CD3xCD20): Results from a phase 1/2 dose-escalation study in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Presented at the 25 <sup>th</sup> Congress of the European Hematology Association; June 11-21, 2020. EHA Library. 2020:EP1330.	<a href="https://library.ehaweb.org/eha/2020/eha25th/293817/christopher.chiu.evaluation.of.pharmacodynamic.biomarkers.of.epcoritamab.html">https://library.ehaweb.org/eha/2020/eha25th/293817/christopher.chiu.evaluation.of.pharmacodynamic.biomarkers.of.epcoritamab.html</a>
Creative Biolabs. ADC Development Services for Non-Hodgkin Lymphoma (NHL) Research.	<a href="https://www.creative-biolabs.com/adc/adc-development-for-nhl.htm">https://www.creative-biolabs.com/adc/adc-development-for-nhl.htm</a>
Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. <i>N Engl J Med</i> . 2022;387:2220-2231.	<a href="https://www.nejm.org/doi/10.1056/NEJMoa2206913">https://www.nejm.org/doi/10.1056/NEJMoa2206913</a>
Dickinson M, Carlo-Stella C, Morschhauser F, et al. Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and $\geq 2$ prior therapies: Pivotal phase II expansion results. <i>J Clin Oncol</i> . 2022;40(16 suppl):7500.	<a href="https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7500">https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7500</a>
Duell J, Maddocks KJ, González-Barca E, et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. <i>Haematologica</i> . 2021;106:2417-2426.	<a href="https://haematologica.org/article/view/haematol.2020.275958">https://haematologica.org/article/view/haematol.2020.275958</a>
Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. <i>EBioMedicine</i> . 2020;52:102625.	<a href="https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(19)30840-0/fulltext">https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(19)30840-0/fulltext</a>

González Barca E. Role of bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma in the CART era. <i>Front Immunol.</i> 2022;13:909008.	<a href="https://www.frontiersin.org/articles/10.3389/fimmu.2022.909008/full">https://www.frontiersin.org/articles/10.3389/fimmu.2022.909008/full</a>
Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. <i>J Clin Oncol.</i> 2021;39:1959-1970.	<a href="https://ascopubs.org/doi/10.1200/JCO.20.03175">https://ascopubs.org/doi/10.1200/JCO.20.03175</a>
Hutchings M, Mous R, Clausen MR, et al. Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with prior CAR-T therapy: Updated dose escalation data. <i>Blood.</i> 2020;136(suppl 1):45-46.	<a href="https://ashpublications.org/blood/article/136/Supplement%201/45/470017/Subcutaneous-Epcoritamab-Induces-Complete">https://ashpublications.org/blood/article/136/Supplement%201/45/470017/Subcutaneous-Epcoritamab-Induces-Complete</a>
Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1/2 study. <i>Lancet.</i> 2021;398:1157-1169.	<a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00889-8/fulltext">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00889-8/fulltext</a>
Kim TM, Alonso A, Prince M, et al. A phase 2 study of odronextamab (REGN1979), a CD20 x CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Blood.</i> 2020;136(suppl 1):28-29.	<a href="https://ashpublications.org/blood/article/136/Supplement%201/28/472688/A-Phase-2-Study-of-Odronextamab-REGN1979-a-CD20-x">https://ashpublications.org/blood/article/136/Supplement%201/28/472688/A-Phase-2-Study-of-Odronextamab-REGN1979-a-CD20-x</a>
Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood.</i> 2014;124:188-195.	<a href="https://ashpublications.org/blood/article/124/2/188/32896/Current-concepts-in-the-diagnosis-and-management">https://ashpublications.org/blood/article/124/2/188/32896/Current-concepts-in-the-diagnosis-and-management</a>
Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. <i>Biol Blood Marrow Transplant.</i> 2019;25:625-638.	<a href="https://www.astctjournal.org/article/S1083-8791(18)31691-4/fulltext">https://www.astctjournal.org/article/S1083-8791(18)31691-4/fulltext</a>
Minson A, Dickinson M. Glofitamab CD20-TCB bispecific antibody. <i>Leuk Lymphoma.</i> 2021;62:3098-3108.	<a href="https://www.tandfonline.com/doi/abs/10.1080/10428194.2021.1953016">https://www.tandfonline.com/doi/abs/10.1080/10428194.2021.1953016</a>
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology. B-Cell Lymphomas. Version 1.2024.	<a href="https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf">https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf</a>
Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. <i>Nat Rev Clin Oncol.</i> 2018;15:47-62.	<a href="https://www.nature.com/articles/nrclinonc.2017.148">https://www.nature.com/articles/nrclinonc.2017.148</a>
Nie S, Wang Z, Moscoso-Castro M, et al. Biology drives the discovery of bispecific antibodies as innovative therapeutics. <i>Antib Ther.</i> 2020;3:18-62.	<a href="https://academic.oup.com/abt/article/3/1/18/5739255">https://academic.oup.com/abt/article/3/1/18/5739255</a>
Northend M, Wilson W, Osborne W, et al. Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. <i>Blood Adv.</i> 2022;6:2920-2926.	<a href="https://ashpublications.org/bloodadvances/article/6/9/2920/483452/Results-of-a-United-Kingdom-real-world-study-of">https://ashpublications.org/bloodadvances/article/6/9/2920/483452/Results-of-a-United-Kingdom-real-world-study-of</a>
Phillips T, Dickenson M, Morschhauser F, et al. Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma. Presented at the 64th ASH Annual Meeting; December 10–13, 2022.	<a href="https://medically.gene.com/global/en/unrestricted/haematology/ASH-2022/ash-2022-presentation-phillips-glofitamab-monotherapy-i.html">https://medically.gene.com/global/en/unrestricted/haematology/ASH-2022/ash-2022-presentation-phillips-glofitamab-monotherapy-i.html</a>

Phillips T, Dickenson M, Morschhauser F, et al. Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma. <i>Blood</i> . 2022;140(suppl 1):178-180.	<a href="https://ashpublications.org/blood/article/140/Supplement%201/178/489039/Glofitamab-Monotherapy-Induces-High-Complete">https://ashpublications.org/blood/article/140/Supplement%201/178/489039/Glofitamab-Monotherapy-Induces-High-Complete</a>
Qualls DA, Lambert N, Caimi PF, et al. Tafasitamab and lenalidomide in large B-cell lymphoma: Real-world outcomes in a multicenter retrospective study. <i>Blood</i> . 2023;142:2327-2331.	<a href="https://ashpublications.org/blood/article-abstract/142/26/2327/498041/Tafasitamab-and-lenalidomide-in-large-B-cell">https://ashpublications.org/blood/article-abstract/142/26/2327/498041/Tafasitamab-and-lenalidomide-in-large-B-cell</a>
Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. <i>J Clin Oncol</i> . 2020;38:155-165.	<a href="https://ascopubs.org/doi/10.1200/JCO.19.00172">https://ascopubs.org/doi/10.1200/JCO.19.00172</a>
Smith EJ, Olson K, Haber LJ, et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. <i>Sci Rep</i> . 2015;5:17943.	<a href="https://www.nature.com/articles/srep17943">https://www.nature.com/articles/srep17943</a>
Sun LL, Ellerman D, Mathieu M, et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. <i>Sci Transl Med</i> . 2015;7:287ra70.	<a href="https://www.science.org/doi/10.1126/scitranslmed.aaa4802">https://www.science.org/doi/10.1126/scitranslmed.aaa4802</a>
Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II Trial. <i>J Clin Oncol</i> . 2023;41:2238-2247.	<a href="https://ascopubs.org/doi/10.1200/JCO.22.01725">https://ascopubs.org/doi/10.1200/JCO.22.01725</a>
Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. <i>N Engl J Med</i> . 2022;386:351-363.	<a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2115304">https://www.nejm.org/doi/full/10.1056/NEJMoa2115304</a>

All URLs accessed March 14, 2024